Clinic
Mount ST. Mary's Hospital of Niagara Falls
Mount ST. Mary's Hospital of Niagara Falls was paid $22.19M by Medicaid between Jan 2018 and Dec 2024, across 295 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 29% of everything it billed.
33Billing provider infoMOUNT ST. MARY'S HOSPITAL OF NIAGARA FALLS
LEWISTON, NY 14092
LEWISTON, NY 14092
33aNPI1043394745assigned 10/25/2006
33bProvider typeCardiac Rehabilitation Clinic/Center
28Total paid$22.19M
24GClaims588,718
24DCodes billed295
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Cardiac Rehabilitation Clinic/Center providers in New York
Rank by total paid#2 of 5
Median peer was paid$13.42M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,203 | $349K | |
| 2019 | 39,956 | $1.16M | |
| 2020 | 80,496 | $2.20M | |
| 2021 | 100,216 | $3.74M | |
| 2022 | 106,837 | $4.20M | |
| 2023 | 125,487 | $5.41M | |
| 2024incomplete | 130,523 | $5.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 29% | 62,424 | 51,399 | $6.50M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 15,536 | 14,847 | $2.39M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.2% | 11,777 | 11,075 | $1.82M |
| G0378 | Hospital observation service, per hour | 5.8% | 1,327 | 830 | $1.28M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.0% | 4,913 | 4,552 | $880K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 6,004 | 5,864 | $851K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 2,485 | 2,422 | $553K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.4% | 6,793 | 6,441 | $530K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 2,119 | 2,076 | $445K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.0% | 22,015 | 17,912 | $443K |
| 80053 | Comprehensive metabolic panel | 1.8% | 25,616 | 22,516 | $394K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 1,419 | 1,390 | $314K |
283 more codes
| 99285 | Emergency room visit (most serious) | 1.4% | 1,843 | $310K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 2,447 | $253K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 4,154 | $242K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,820 | $214K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,151 | $200K |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,353 | $180K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,132 | $173K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,245 | $167K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 327 | $151K |
| 99201 | <1% | 1,385 | $140K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,078 | $137K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,487 | $134K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,711 | $133K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,307 | $121K |
| 87481 | <1% | 3,425 | $121K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,319 | $119K |
| 87631 | <1% | 2,628 | $116K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 516 | $114K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,717 | $103K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,274 | $92K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 790 | $85K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,163 | $83K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,391 | $74K |
| 97597 | <1% | 274 | $71K | |
| 20610 | <1% | 317 | $70K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 42 | $69K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 301 | $69K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,446 | $69K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,684 | $65K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,231 | $61K |
| 76830 | Ultrasound, transvaginal | <1% | 1,537 | $55K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,513 | $54K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 392 | $51K |
| 99442 | <1% | 736 | $50K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,561 | $50K |
| 80061 | Lipid panel | <1% | 7,269 | $49K |
| 90715 | <1% | 1,927 | $49K | |
| 97161 | <1% | 792 | $47K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,013 | $47K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 767 | $46K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 717 | $46K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,829 | $44K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,018 | $43K |
| 12001 | <1% | 114 | $40K | |
| 69210 | <1% | 1,383 | $40K | |
| 82607 | <1% | 4,295 | $40K | |
| 76801 | <1% | 550 | $38K | |
| 86850 | <1% | 1,778 | $37K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,894 | $31K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 24,847 | $31K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 384 | $30K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 349 | $29K |
| 83880 | <1% | 1,253 | $29K | |
| 90686 | <1% | 1,063 | $27K | |
| 84439 | <1% | 3,465 | $27K | |
| 99441 | <1% | 323 | $27K | |
| 93017 | <1% | 909 | $26K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 306 | $25K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,426 | $24K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 215 | $24K |
| 86900 | <1% | 2,109 | $22K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,006 | $22K |
| 81025 | <1% | 7,646 | $22K | |
| 76641 | <1% | 906 | $22K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,562 | $20K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,200 | $19K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 192 | $18K |
| 82803 | <1% | 862 | $17K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,848 | $17K |
| 93976 | <1% | 42 | $16K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,351 | $16K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 51 | $16K |
| 82746 | <1% | 1,477 | $15K | |
| 93971 | <1% | 314 | $15K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,644 | $15K |
| 87563 | <1% | 698 | $13K | |
| 82728 | <1% | 1,171 | $13K | |
| 87660 | <1% | 6,495 | $11K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,859 | $11K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 129 | $11K |
| 84702 | <1% | 2,001 | $11K | |
| 93970 | <1% | 53 | $11K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 271 | $11K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,431 | $10K |
| 90682 | <1% | 378 | $10K | |
| 85027 | <1% | 4,072 | $10K | |
| 86803 | <1% | 1,598 | $10K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 274 | $9K |
| 81001 | <1% | 10,494 | $9K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 66 | $9K |
| 86701 | <1% | 977 | $9K | |
| 99221 | <1% | 110 | $9K | |
| 76536 | <1% | 427 | $8K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,530 | $7K |
| 83921 | <1% | 473 | $7K | |
| 71271 | <1% | 323 | $7K | |
| 86901 | <1% | 476 | $7K | |
| 80076 | <1% | 759 | $7K | |
| 82043 | <1% | 1,527 | $6K | |
| 85610 | <1% | 4,191 | $6K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 288 | $6K |
| 86762 | <1% | 610 | $6K | |
| 76818 | <1% | 158 | $6K | |
| 83550 | <1% | 1,350 | $5K | |
| 87340 | <1% | 754 | $5K | |
| 99443 | <1% | 69 | $5K | |
| 87088 | <1% | 1,771 | $5K | |
| 90670 | <1% | 134 | $5K | |
| 85730 | <1% | 3,581 | $5K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 50 | $4K |
| 59025 | Fetal non-stress test | <1% | 108 | $4K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 54 | $4K |
| 12011 | <1% | 13 | $4K | |
| 93225 | <1% | 220 | $4K | |
| 70486 | <1% | 45 | $4K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 41 | $4K |
| 83735 | <1% | 3,625 | $4K | |
| 90656 | <1% | 260 | $4K | |
| 76813 | <1% | 63 | $3K | |
| 71250 | <1% | 53 | $3K | |
| 31575 | <1% | 126 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,960 | $3K |
| 87077 | <1% | 2,202 | $3K | |
| 90734 | <1% | 144 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 168 | $3K |
| 99406 | <1% | 92 | $3K | |
| 84153 | <1% | 197 | $3K | |
| 83655 | <1% | 201 | $3K | |
| 87186 | <1% | 1,960 | $3K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $3K |
| 81003 | <1% | 4,951 | $2K | |
| 73630 | <1% | 1,144 | $2K | |
| 73030 | <1% | 751 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,578 | $2K |
| 87480 | <1% | 1,726 | $2K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 30 | $2K |
| 87510 | <1% | 1,724 | $2K | |
| 83690 | <1% | 5,717 | $2K | |
| 72100 | <1% | 365 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 56 | $2K |
| 31231 | <1% | 168 | $2K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,111 | $2K |
| 85652 | <1% | 1,218 | $2K | |
| 86787 | <1% | 297 | $2K | |
| 86885 | <1% | 54 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,000 | $2K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 67 | $1K |
| 97162 | <1% | 13 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,703 | $1K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 73 | $1K |
| 82150 | <1% | 2,924 | $1K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 40 | $1K |
| 95819 | <1% | 39 | $1K | |
| 99385 | <1% | 19 | $1K | |
| 81513 | <1% | 3,455 | $1K | |
| 88304 | <1% | 230 | $1K | |
| 83001 | <1% | 89 | $1K | |
| 82570 | <1% | 275 | $1K | |
| 72110 | <1% | 81 | $1K | |
| 90651 | <1% | 36 | $1K | |
| 86140 | <1% | 424 | $1K | |
| 99000 | <1% | 247 | $1K | |
| 73562 | <1% | 440 | $1K | |
| 95886 | <1% | 32 | $1K | |
| 83540 | <1% | 202 | $988.04 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $952.03 |
| 73130 | <1% | 654 | $942.73 | |
| 73610 | <1% | 829 | $913.82 | |
| 97010 | <1% | 53 | $903.33 | |
| 73564 | <1% | 286 | $897.24 | |
| 82784 | <1% | 59 | $878.78 | |
| 86480 | <1% | 14 | $826.82 | |
| 90677 | <1% | 12 | $779.45 | |
| 74018 | <1% | 308 | $762.56 | |
| 84484 | <1% | 6,394 | $730.30 | |
| 73502 | <1% | 202 | $725.71 | |
| 84550 | <1% | 213 | $640.98 | |
| 86580 | <1% | 137 | $632.15 | |
| 86003 | <1% | 21 | $632.07 | |
| 86038 | <1% | 153 | $579.08 | |
| 82950 | <1% | 144 | $571.47 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 80 | $551.74 |
| 90714 | <1% | 25 | $535.98 | |
| 82550 | <1% | 387 | $527.13 | |
| 82948 | <1% | 3,943 | $523.34 | |
| 86592 | <1% | 180 | $511.42 | |
| 83605 | <1% | 1,774 | $502.42 | |
| 85379 | <1% | 1,129 | $469.96 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 15 | $463.35 |
| 86376 | <1% | 38 | $461.91 | |
| 86880 | <1% | 25 | $457.88 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,257 | $451.59 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,106 | $428.18 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,035 | $426.22 |
| 87040 | <1% | 1,688 | $424.07 | |
| 87070 | <1% | 556 | $378.82 | |
| 73110 | <1% | 309 | $371.97 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,634 | $367.98 |
| 90713 | <1% | 13 | $326.30 | |
| 90632 | <1% | 12 | $288.92 | |
| 84156 | <1% | 131 | $271.69 | |
| 85007 | <1% | 589 | $248.91 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 934 | $226.93 |
| 84100 | <1% | 65 | $209.08 | |
| 84480 | <1% | 39 | $191.26 | |
| 93016 | <1% | 12 | $181.50 | |
| 74019 | <1% | 99 | $173.98 | |
| 83021 | <1% | 13 | $173.60 | |
| 86800 | <1% | 13 | $153.83 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,162 | $152.81 |
| 83002 | <1% | 12 | $148.53 | |
| 93018 | <1% | 12 | $148.50 | |
| 81002 | <1% | 1,296 | $148.22 | |
| 72040 | <1% | 24 | $144.61 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,365 | $143.59 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 125 | $139.31 |
| 82565 | <1% | 55 | $122.61 | |
| 84460 | <1% | 53 | $114.14 | |
| 84703 | <1% | 1,076 | $101.64 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 629 | $100.06 |
| 82310 | <1% | 56 | $98.96 | |
| 87205 | <1% | 267 | $96.87 | |
| 84520 | <1% | 54 | $93.78 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,522 | $93.43 |
| 87081 | <1% | 753 | $92.88 | |
| 84481 | <1% | 13 | $90.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,299 | $81.04 |
| A9270 | Non-covered item or service | <1% | 14,414 | $74.95 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,015 | $69.64 |
| 82248 | <1% | 15 | $66.30 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 676 | $62.29 |
| G0008 | Administration of influenza virus vaccine | <1% | 17 | $58.85 |
| 84436 | <1% | 13 | $55.88 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 414 | $50.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,624 | $35.51 |
| 73080 | <1% | 30 | $33.76 | |
| 80320 | <1% | 367 | $30.15 | |
| 71101 | <1% | 13 | $26.04 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 776 | $25.14 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 75 | $19.48 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 151 | $18.09 |
| 81015 | <1% | 182 | $17.76 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,162 | $16.35 |
| 85018 | <1% | 124 | $12.12 | |
| 73090 | <1% | 14 | $12.12 | |
| 82947 | <1% | 14 | $11.79 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 204 | $11.72 |
| 80355 | <1% | 262 | $11.54 | |
| 80369 | <1% | 261 | $10.68 | |
| 85014 | <1% | 122 | $10.10 | |
| 73590 | <1% | 12 | $10.10 | |
| 86308 | <1% | 13 | $9.56 | |
| 87075 | <1% | 27 | $9.47 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 880 | $8.46 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 212 | $7.62 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 211 | $7.30 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 360 | $6.83 |
| J3490 | Unclassified drugs | <1% | 325 | $5.83 |
| 87802 | <1% | 204 | $5.75 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 192 | $5.04 |
| 82040 | <1% | 12 | $4.95 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 76 | $4.68 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 38 | $4.18 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 275 | $2.16 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 120 | $1.17 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 603 | $1.03 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 59 | $0.74 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 255 | $0.68 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 86 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 48 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 94 | $0.00 |
| 99152 | 0% | 39 | $0.00 | |
| 82010 | 0% | 42 | $0.00 | |
| 80179 | 0% | 13 | $0.00 | |
| 80354 | 0% | 17 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 55 | $0.00 |
| 93041 | 0% | 15 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 237 | $0.00 |
| 96376 | 0% | 1,228 | $0.00 | |
| 80368 | 0% | 14 | $0.00 | |
| 80329 | 0% | 27 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 14 | $0.00 |
| 80358 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMACHOLZ, DAVID (CFO)
| Provider | Location | Paid |
|---|---|---|
| Mercy Hospital of Buffalo | Buffalo, NY | $29.86M |
| Sisters of Charity Hospital of Buffalo New York | Cheektowaga, NY | $13.42M |
| Sisters of Charity Hospital of Buffalo New York | Buffalo, NY | $3.93M |
| Mount ST. Mary's Hospital of Niagara Falls | Lewiston, NY | $2.87M |
| Mercy Hospital of Buffalo | Buffalo, NY | $449K |
| Kenmore Mercy Hospital | Kenmore, NY | $70K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.